(Washington, D.C.) — In honor of World Diabetes Day, the Pharmaceutical Care Management Association (PCMA) has launched a new phase of the OnYourRxSide campaign that showcases how pharmacy benefit managers, PBMs, are working to improve the lives of patients living
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, released a new episode, “Understanding Prescription Drug Rebates.” The podcast episode, hosted by PCMA President and CEO JC Scott, features Alex Brill, a health policy researcher and founder
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act will increase taxpayer spending by approximately $23 billion over 10 years. Pharmacy benefit managers, PBMs,
(Washington, D.C.) — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to a new Visante analysis: “Insulins: Managing Costs with Increasing Manufacturer Prices.” The Visante analysis finds that insulin list prices escalated
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
New report from the Congressional Budget Office highlights the value of PBMs in keeping net drug costs low for payers and patients.
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
Court Ruling Finds that ERISA Preempts State PBM Law COURT REJECTS BID TO PREEMPT ERISA…In a unanimous decision, the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready court sustained PCMA’s challenge to four provisions in
(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
(Washington, D.C.) — A new report, prepared by the research firm Milliman, analyzed the financial impact of broad “Frozen Formulary” legislation in the fully insured commercial market on a nationwide basis. This study found that “Frozen Formulary” legislation could increase nationwide
©2024 PCMA. All Rights Reserved.
